Aurinia Pharmaceuticals Inc (AUPH): Price and Financial Metrics

Aurinia Pharmaceuticals Inc (AUPH)

Today's Latest Price: $15.68 USD

0.34 (-2.12%)

Updated Oct 30 4:00pm

Add AUPH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AUPH Stock Summary

  • The ratio of debt to operating expenses for Aurinia Pharmaceuticals Inc is higher than it is for about only 8.39% of US stocks.
  • With a price/sales ratio of 5,512.57, Aurinia Pharmaceuticals Inc has a higher such ratio than 99.75% of stocks in our set.
  • With a year-over-year growth in debt of 1,405.34%, Aurinia Pharmaceuticals Inc's debt growth rate surpasses 98.49% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Aurinia Pharmaceuticals Inc, a group of peers worth examining would be VTVT, VNRX, MRTX, RVNC, and ADVM.
  • AUPH's SEC filings can be seen here. And to visit Aurinia Pharmaceuticals Inc's official web site, go to

AUPH Stock Price Chart Interactive Chart >

Price chart for AUPH

AUPH Price/Volume Stats

Current price $15.68 52-week high $21.93
Prev. close $16.02 52-week low $4.70
Day low $15.50 Volume 617,200
Day high $16.05 Avg. volume 1,404,176
50-day MA $14.85 Dividend yield N/A
200-day MA $15.72 Market Cap 1.98B

Aurinia Pharmaceuticals Inc (AUPH) Company Bio

Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutic] The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. The company was founded in 1993 and is based in Victoria, Canada.

AUPH Latest News Stream

Event/Time News Detail
Loading, please wait...

AUPH Latest Social Stream

Loading social stream, please wait...

View Full AUPH Social Stream

Latest AUPH News From Around the Web

Below are the latest news stories about Aurinia Pharmaceuticals Inc that investors may wish to consider to help them evaluate AUPH as an investment opportunity.

Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (Aurinia or the Company), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple autoimmune conditions, today announced that the last patient study visit has occurred in the Phase 2/3 AUDREY™ clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing vi

Business Wire | September 28, 2020

Aurinia Pharmaceuticals Inc (AUPH) Investor Presentation - Slideshow

The following slide deck was published by Aurinia Pharmaceuticals Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 15, 2020

Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that the Company’s Compensation Committee granted 105 new employees non-qualified stock options to purchase an aggregate of 530,000 common shares, at a per share exercise price of $14.83 USD, the closing trading price on August 31,

Business Wire | September 4, 2020

Aurinia Pharmaceuticals, Inc.'s (AUPH) CEO Peter Greenleaf on Q2 2020 Results - Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2020 Results Earnings Conference Call August 11, 2020, 04:30 PM ET Company Participants Glenn Schulman - SVP, Corporate Communications and IR Peter Greenleaf - CEO and Director Neil Solomons - Chief Medical Officer Max Colao - Chief Commercial Officer Joe Miller - Chief Financial Officer...

SA Transcripts on Seeking Alpha | August 12, 2020

Recap: Aurinia Pharmaceuticals Q2 Earnings

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) were unchanged after-market trading after the company reported Q2 results. Quarterly Results Earnings …

Benzinga | August 11, 2020

Read More 'AUPH' Stories Here

AUPH Price Returns

1-mo 7.18%
3-mo 10.97%
6-mo -4.56%
1-year 205.65%
3-year 173.17%
5-year 419.21%
YTD -22.61%
2019 197.07%
2018 50.55%
2017 115.71%
2016 -14.98%
2015 -32.14%

Continue Researching AUPH

Here are a few links from around the web to help you further your research on Aurinia Pharmaceuticals Inc's stock as an investment opportunity:

Aurinia Pharmaceuticals Inc (AUPH) Stock Price | Nasdaq
Aurinia Pharmaceuticals Inc (AUPH) Stock Quote, History and News - Yahoo Finance
Aurinia Pharmaceuticals Inc (AUPH) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8201 seconds.